{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.656"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Toxicity assessed using CTCAE v4.0 will be defined as the proportion of patients who experience one or more grade 3 or 4 adverse event or serious adverse event of any grade","groups":[{"description":"Avelumab 10mg/kg by IV infusion once every 2 weeks. A maximum of 8 cycles, each cycle is 28 days.\n\nAvelumab: anti-PDL1 antibody","id":"OG000","title":"Avelumab"}],"paramType":"NUMBER","populationDescription":"The proportion of patients in the per-protocol population who experience one or more grade 3 or 4 adverse event or serious adverse event of any grade","reportingStatus":"POSTED","timeFrame":"During treatment of 8 cycles (224 days)","title":"Toxicity- Proportion of Patients","type":"SECONDARY","unitOfMeasure":"proportion of patients"}